International Clinical Trial: Tremelimumab as adjuvant therapy for non-small cell lung cancer without neoadjuvant treatment and with PD-L1 TPS = 1: A single-arm, single-center phase I clinical study

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132065) titled 'Tremelimumab as adjuvant therapy for non-small cell lung cancer without neoadjuvant treatment and with PD-L1 TPS = 1: A single-arm, single-center phase I clinical study' on Sept. 9.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The Affiliated Hospital of Qingdao University

Condition: Non-small cell lung cancer without neoadjuvant therapy and with PD-L1 TPS = 1

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-10-15

Target Sample Size: Experimental group:76;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.h...